Abstract
Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Current Alzheimer Research
Title: A New Model for Academics Based Drug Discovery
Volume: 4 Issue: 5
Author(s): Ross L. Stein
Affiliation:
Keywords: Harvard Center for Neurodegeneration and Repair, Drug Discovery, Medicinal Chemistry, Laboratory for Drug Discovery in Neurodegeneration, pharmaceutical company
Abstract: Drug discovery is a complex and costly endeavor, requiring multidisciplinary know-how, interdisciplinary collaboration, tenacity, and a bit of luck. For these reasons, the search for new chemical agents to treat human disease has traditionally been undertaken only within the walls of industry. While the pharmaceutical industry is often successful where it focuses its attention, it generally focuses only on those areas that are allowed by corporate financial realities. Sadly, this means that diseases effecting small populations of patients may go untreated. As a society we should not be content with this situation and must make a priority of the development of new models that will allow and encourage drug discovery in disease areas that are neglected by pharma. In this presentation, I will describe one such model that has been established to find treatments for neurodegenerative diseases.
Export Options
About this article
Cite this article as:
Stein L. Ross, A New Model for Academics Based Drug Discovery, Current Alzheimer Research 2007; 4 (5) . https://dx.doi.org/10.2174/156720507783018280
DOI https://dx.doi.org/10.2174/156720507783018280 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurotrophic Factors in the Pathogenesis of Neurological Disorders with Mental Retardation in Children
Current Pediatric Reviews Potential Control of Multiple Sclerosis by Cannabis and the Endocannabinoid System
CNS & Neurological Disorders - Drug Targets Nanoemulsions for Intranasal Delivery of Riluzole to Improve Brain Bioavailability: Formulation Development and Pharmacokinetic Studies
Current Drug Delivery Tianeptine: A Novel Atypical Antidepressant that May Provide New Insights into the Biomolecular Basis of Depression
Recent Patents on CNS Drug Discovery (Discontinued) RAGE, Diabetes, and the Nervous System
Current Molecular Medicine Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy
Current Pharmaceutical Design GEMSP: A New Therapeutic Approach to Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective
CNS & Neurological Disorders - Drug Targets The Effect of Lipoic Acid on Macro and Trace Metal Levels in Living Tissues Exposed to Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Memory-Enhancing Drugs: A Molecular Perspective
Mini-Reviews in Medicinal Chemistry Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Current Medicinal Chemistry MAPKs as Mediators of Cell Fate Determination: an Approach to Neurodegenerative Diseases
Current Medicinal Chemistry Stem Cells: In Sickness and in Health
Current Stem Cell Research & Therapy Sirtuins: Nodes Connecting Aging, Metabolism and Tumorigenesis
Current Pharmaceutical Design α-Synuclein Misfolding and Neurodegenerative Diseases
Current Protein & Peptide Science Synthetic Cannabinoid Receptor Agonists and Antagonists: Implication in CNS Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
Reviews on Recent Clinical Trials Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?
CNS & Neurological Disorders - Drug Targets Cell-Replacement Therapy with Stem Cells in Neurodegenerative Diseases
Current Neurovascular Research Insights into the Structure, Function, and Regulation of Human Cytochrome P450 1A2
Current Drug Metabolism